The Deubiquitinating Enzyme UCH37 Interacts with Smads and Regulates TGF-β Signalling

Stephen J Wicks,Katherine Haros,Marjorie Maillard,Ling Song,Robert E Cohen,Peter ten Dijke,Andrew Chantry
DOI: https://doi.org/10.1038/sj.onc.1208944
IF: 8.756
2005-01-01
Oncogene
Abstract:Disruption of components in the transforming growth factor-β (TGF-β) signalling cascade is a common occurrence in human cancers. TGF-β pathway activation is accomplished via serine/threonine kinase receptors and intracellular Smad transcription factors. A key regulatory step involves specific ubiquitination by Smurfs that mediate the proteasomal degradation of Smads and/or receptors. Here, we report a novel interaction between Smads and ubiquitin C-terminal hydrolase UCH37, a deubiquitinating enzyme that could potentially reverse Smurf-mediated ubiquitination. In GST pull down experiments, UCH37 bound weakly to Smad2 and Smad3 and bound very strongly to Smad7 in a region that is distinct from the –PY– motif in Smad7 that interacts with Smurf ubiquitin ligases. Endogenous Smad7 and UCH37 formed a stable complex in U4A/JAK1 cells and FLAG-Smad7 co-immunoprecipitated with HA-UCH37 in transfected HEK-293 cells. In addition, we show that UCH37 can deubiquitinate and stabilize the type I TGF-β receptor. Furthermore, overexpression of UCH37 upregulates TGF-β-dependent transcription and this effect is reversed in cells subject to RNAi-mediated knockdown of endogenous UCH37. These findings support a new role for deubiquitinating enzymes in the control of the TGF-β signalling pathway and provide a novel molecular target for the design of inhibitors with therapeutic potential in cancer.
What problem does this paper attempt to address?